Stanislas Pol

42.7k total citations · 5 hit papers
484 papers, 18.9k citations indexed

About

Stanislas Pol is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Stanislas Pol has authored 484 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 423 papers in Hepatology, 357 papers in Epidemiology and 72 papers in Infectious Diseases. Recurrent topics in Stanislas Pol's work include Hepatitis C virus research (378 papers), Liver Disease Diagnosis and Treatment (267 papers) and Hepatitis B Virus Studies (242 papers). Stanislas Pol is often cited by papers focused on Hepatitis C virus research (378 papers), Liver Disease Diagnosis and Treatment (267 papers) and Hepatitis B Virus Studies (242 papers). Stanislas Pol collaborates with scholars based in France, United States and Germany. Stanislas Pol's co-authors include Anaïs Vallet‐Pichard, Bertrand Nalpas, Vincent Mallet, Christian Bréchot, Hélène Fontaine, Virginie Verkarre, Valérie Dhalluin-Venier, P. Cacoub, Marc Bourlière and Valérie Thiers and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Stanislas Pol

460 papers receiving 18.4k citations

Hit Papers

FIB-4 2002 2026 2010 2018 2007 2009 2002 2015 2017 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FIB-4
    2007 1.6k citations Anaïs Vallet‐Pichard, Vincent Mallet et al. Hepatology profile →
  2. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
    2009 771 citations Christophe Hézode, Stanislas Pol et al. profile →
  3. Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles
    2002 530 citations Stanislas Pol et al. profile →
  4. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
    2015 477 citations Annette Bruchfeld, Stanislas Pol et al. profile →
  5. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
    2017 271 citations Eric Lawitz, Stanislas Pol et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stanislas Pol 15.1k 14.2k 3.1k 1.2k 1.1k 484 18.9k
Ira M. Jacobson 17.0k 1.1× 15.7k 1.1× 3.0k 0.9× 1.5k 1.3× 939 0.9× 338 19.9k
Geoffrey Dusheiko 15.1k 1.0× 14.6k 1.0× 2.4k 0.8× 915 0.8× 1.6k 1.5× 285 18.6k
Mark Sulkowski 22.5k 1.5× 20.6k 1.5× 6.2k 2.0× 1.6k 1.3× 983 0.9× 411 26.9k
Francesco Negro 12.4k 0.8× 12.2k 0.9× 1.5k 0.5× 1.0k 0.8× 833 0.8× 311 16.0k
Masashi Mizokami 16.3k 1.1× 16.1k 1.1× 2.2k 0.7× 872 0.7× 1.4k 1.4× 489 21.8k
Edward Gane 18.3k 1.2× 17.8k 1.3× 2.7k 0.9× 618 0.5× 960 0.9× 454 21.7k
Jean–Michel Pawlotsky 19.7k 1.3× 17.6k 1.2× 3.5k 1.1× 1.9k 1.6× 1.5k 1.4× 467 24.6k
Eugene R. Schiff 22.8k 1.5× 22.5k 1.6× 3.2k 1.0× 1.3k 1.1× 898 0.8× 372 28.9k
Christoph Sarrazin 10.8k 0.7× 10.4k 0.7× 2.5k 0.8× 897 0.7× 695 0.7× 329 13.8k
Janice K. Albrecht 23.6k 1.6× 21.7k 1.5× 2.9k 0.9× 2.5k 2.1× 946 0.9× 117 26.0k

Countries citing papers authored by Stanislas Pol

Since Specialization
Citations

This map shows the geographic impact of Stanislas Pol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanislas Pol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanislas Pol more than expected).

Fields of papers citing papers by Stanislas Pol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanislas Pol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanislas Pol. The network helps show where Stanislas Pol may publish in the future.

Co-authorship network of co-authors of Stanislas Pol

This figure shows the co-authorship network connecting the top 25 collaborators of Stanislas Pol. A scholar is included among the top collaborators of Stanislas Pol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanislas Pol. Stanislas Pol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baquero, Eduard, Cyril Planchais, Virginie Doceul, et al.. (2025). Structural basis for hepatitis E virus neutralization by potent human antibodies. Science Advances. 11(19). eadu8811–eadu8811.
2.
Poynard, Thierry, Olivier Deckmyn, Valentina Peta, et al.. (2023). Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis. Alimentary Pharmacology & Therapeutics. 58(9). 888–902. 5 indexed citations
3.
Awan, Ahmed A., Marina Berenguer, Annette Bruchfeld, et al.. (2023). Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Annals of Internal Medicine. 176(12). 1648–1655. 5 indexed citations
4.
Gaston, Jésintha, Estelle Mottez, Pierre‐Philippe Massault, et al.. (2022). IL-17A in Human Liver: Significant Source of Inflammation and Trigger of Liver Fibrosis Initiation. International Journal of Molecular Sciences. 23(17). 9773–9773. 13 indexed citations
5.
Nahon, Pierre, Richard Layese, Carole Cagnot, et al.. (2021). HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. Cancer Prevention Research. 14(5). 581–592. 1 indexed citations
6.
7.
Beretta, Maxime, Maryline Bourgine, Malika Ait‐Goughoulte, et al.. (2020). Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. The Journal of Experimental Medicine. 217(10). 44 indexed citations
8.
Mallet, Vincent, Lucia Parlati, Anaïs Vallet‐Pichard, et al.. (2019). L’index FIB-4 pour faire le diagnostic de fibrose hépatique avancée au cours de la stéatose hépatique. La Presse Médicale. 48(12). 1484–1488. 5 indexed citations
9.
Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology. 67(4). 1253–1260. 105 indexed citations
10.
Younossi, Zobair M., Maria Stepanova, Stanislas Pol, et al.. (2015). The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver International. 36(1). 42–48. 45 indexed citations
11.
Fontaine, Hélène, Sandrine Kahi, Cyrille Chazallon, et al.. (2014). Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN. Gut. 64(1). 139–147. 78 indexed citations
12.
Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454. 5 indexed citations
13.
Bronowicki, J.‐P., Vlad Ratziu, Adrián Gadano, et al.. (2013). 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016). Journal of Hepatology. 58. S571–S572. 10 indexed citations
14.
15.
Bavu, Éric, Jean‐Luc Gennisson, Vincent Mallet, et al.. (2010). 406 SUPERSONIC SHEAR IMAGING IS A NEW POTENT MORPHOLOGICAL NON-INVASIVE TECHNIQUE TO ASSESS LIVER FIBROSIS. PART I: TECHNICAL FEASABILITY. Journal of Hepatology. 52. S166–S166. 4 indexed citations
16.
Rekacewicz, Claire, Sherif A. El‐Kafrawy, Mohamed Abdel-Hamid, et al.. (2008). Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a. PLoS ONE. 3(12). e4085–e4085. 16 indexed citations
17.
Soussan, Patrick, Jonathan Pol, Florianne Garreau, et al.. (2008). Expression of Defective Hepatitis B Virus Particles Derived from Singly Spliced RNA Is Related to Liver Disease. The Journal of Infectious Diseases. 198(2). 218–225. 52 indexed citations
18.
Esmat, Gamal, Claire Rekacewicz, Khaled Zalata, et al.. (2007). Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.. PubMed. 12(5). 797–803. 40 indexed citations
19.
Pol, Stanislas. (2002). [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].. PubMed. 26 Spec No 2. B264–73.
20.
Pol, Stanislas, et al.. (2000). Immune therapy of hepatitis B virus (HBV) chronic infection. European experience.. PubMed. 63(2). 194–6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by Geoffrey Dusheiko Breakdown of academic impact, for papers by Mark Sulkowski Breakdown of academic impact, for papers by Francesco Negro Breakdown of academic impact, for papers by Masashi Mizokami Breakdown of academic impact, for papers by Edward Gane Breakdown of academic impact, for papers by Jean–Michel Pawlotsky Breakdown of academic impact, for papers by Eugene R. Schiff Breakdown of academic impact, for papers by Christoph Sarrazin Breakdown of academic impact, for papers by Janice K. Albrecht
Rankless by CCL
2026